Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Earnings for Celltrion, Inc. (068270.KS)
Earnings in 2023 (TTM): $462.42 M
According to Celltrion, Inc.'s latest financial reports the company's current earnings (TTM) are $462.42 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Celltrion, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $462.42 M | $369.09 M |
| 2022 | $431.47 M | $370.6 M |
| 2021 | $517.69 M | $399.28 M |
| 2020 | $452.81 M | $356.76 M |
| 2019 | $263.24 M | $207.43 M |
| 2018 | $207.85 M | $169.34 M |
| 2017 | $332.86 M | $253.72 M |
| 2016 | $158.02 M | $122.65 M |
| 2015 | $112.39 M | $106.18 M |
| 2014 | $102.75 M | $77.64 M |
| 2013 | $79.7 M | $70.6 M |
| 2012 | $129.24 M | $120.19 M |
| 2011 | $126.36 M | $115.63 M |
| 2010 | $75.7 M | $74.67 M |
| 2009 | $45.76 M | $40.34 M |
| 2008 | $12.14 M | $10.04 M |
| 2007 | $184.15 K | $1.58 M |